Leap Therapeutics, INC

Cypherpunk Technologies Inc. announced the appointment of Amanda Fabiano to its Board of Directors, effective September 22, 2026, bringing extensive experience in digital asset mining and infrastructure.

Cypherpunk Technologies Inc. has launched the world's largest Zcash mining fleet through a $33.33 million equity transaction, significantly expanding its operational capacity and market presence.

Cypherpunk Technologies announced its second quarter 2026 financial results, highlighting an increase in Zcash holdings and progress for its subsidiary Leap Therapeutics' cancer drug candidate, sirexatamab.

Cypherpunk Technologies Inc. has received a notification from Nasdaq regarding its common stock's closing bid price falling below the $1.00 minimum requirement for continued listing.

Cypherpunk Technologies Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, closing a deficiency matter.

Cypherpunk Technologies announced its first quarter 2026 financial results, highlighting increased Zcash holdings and a strategic investment in Zcash Open Development Labs, alongside updates from its Leap Therapeutics subsidiary.

Cypherpunk Technologies Inc. filed its Q2 2026 10-Q, detailing a shift towards a digital asset treasury strategy alongside its ongoing biopharmaceutical research, marked by a substantial unrealized gain on digital assets but also significant operating losses.

Cypherpunk Technologies Inc. reported its first quarter 2026 financial results, highlighting a significant shift towards a digital asset treasury strategy alongside its ongoing biotechnology operations.

Cypherpunk Technologies Inc. (formerly Leap Therapeutics) has completed a strategic pivot to a digital asset treasury strategy focused on Zcash, raising $58.8 million and appointing new digital asset-focused executives.

Leap Therapeutics reported a significant cash burn and workforce reduction, raising substantial doubt about its ability to continue as a going concern while exploring strategic alternatives.

Leap Therapeutics announces Q1 2025 financial results, provides updates on its clinical programs, and unveils a strategic restructuring to prioritize sirexatamab development in colorectal cancer (CRC).

Leap Therapeutics reported a net loss of $18.2 million for the third quarter of 2024, while continuing to advance its clinical programs.

Cypherpunk Technologies Inc. reports a significant net income for 2025 driven by an unrealized gain on its Zcash holdings, following a strategic pivot to privacy technology while scaling back its biotechnology operations.

Leap Therapeutics' 10-K filing summarizes the company's financial performance for 2024 and provides updates on its clinical development programs, including sirexatamab and FL-501.

Leap Therapeutics' 2023 annual report details significant R&D spending, clinical trial advancements, and a net loss, while emphasizing the potential of their drug candidates.

Khing Djien Oei, a Director of Leap Therapeutics, Inc., sold 168,750 shares of common stock on September 25, 2026 for $3.92 per share.

Patricia A. Martin, a Director of Leap Therapeutics, Inc., sold 50,000 shares of common stock on September 23, 2026 for $3.86 per share.

Thomas John Dietz, a Director of Leap Therapeutics, Inc., sold 20,000 shares of common stock on August 26, 2026 for $1.72 per share.

Kevin Zhang, Head of Mining of Leap Therapeutics, Inc., received 2,000,000 shares of common stock on August 21, 2026.

William Patrick Mcevoy Iii, Chief Investment Officer, a Director and 10% owner of Leap Therapeutics, Inc., reported multiple transactions in common stock on August 17, 2026.

Winklevoss Capital Fund, LLC and 4 others reported changes in beneficial ownership of Leap Therapeutics, Inc. common stock on August 17, 2026.

Cypherpunk Technologies Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, scheduled for June 18, 2026, to elect directors, vote on executive compensation, and ratify auditor appointments.

Cypherpunk Technologies Inc. reminds shareholders of a special meeting on December 15, 2025, to vote on proposals including increasing authorized shares, a reverse stock split, an equity incentive plan, and a private placement issuance.

Leap Therapeutics rebrands as Cypherpunk Technologies, adopts a Zcash treasury strategy, and appoints Khing Oei as Chairman and William McEvoy as CIO.

Leap Therapeutics, Inc. is seeking stockholder approval for proposals including an increase in authorized shares, a reverse stock split, a new equity incentive plan, and the potential issuance of over 19.99% of common stock upon warrant exercise.

Leap Therapeutics calls a special meeting to approve a significant share increase, a potential reverse stock split for Nasdaq compliance, and a new equity plan, following a $58.88 million private placement led by Winklevoss Capital.

Leap Therapeutics will hold its annual shareholder meeting virtually on June 18, 2025, to vote on director elections, executive compensation, and auditor ratification.

Winklevoss entities have significantly increased their beneficial ownership in Cypherpunk Technologies Inc. through warrant exercises and an asset purchase, now holding 19.9% of outstanding shares.

Winklevoss Treasury Investments assigned common warrants for 5.6 million shares of Cypherpunk Technologies to Who Datz LLC for no consideration.

Winklevoss Capital entities have acquired a 19.9% beneficial ownership stake in Leap Therapeutics, Inc. through a private placement, gaining significant board representation.

Gilead Sciences, Inc. has reported a complete divestment of its beneficial ownership in Cypherpunk Technologies Inc., holding 0% of common stock.

Sean Michael Severns filed a Schedule 13G revealing beneficial ownership of 6,000,000 Cypherpunk Technologies shares (10.59%) with sole voting and dispositive power.

Samsara BioCapital, L.P. and its affiliates have reported a complete divestment of their beneficial ownership in Leap Therapeutics, Inc. common stock.

Balyasny Asset Management and its affiliates have filed an amended Schedule 13G, indicating they no longer hold a beneficial ownership stake in Leap Therapeutics, Inc.